Financial Performance - Q2 2025 revenue decreased by 0.8% year-over-year to CHF 732 million, while H1 2025 revenue decreased by 2.1% year-over-year to CHF 1,454 million[40] - Q2 2025 Adjusted EBITDAaL increased by 1.9% year-over-year to CHF 254 million, representing 34.7% of revenue, while H1 2025 Adjusted EBITDAaL increased by 1.1% year-over-year to CHF 494 million, representing 34.0% of revenue[40] - Q2 2025 CAPEX decreased by 7.9% year-over-year to CHF 116 million, representing 15.9% of revenue[40] - Q2 2025 Adjusted Free Cash Flow was CHF 153 million[40] - Sunrise reconfirmed its FY 2025 guidance, expecting broadly stable revenue, stable to low-single digit growth in Adjusted EBITDAaL, CAPEX/Revenue between 15-16%, and Adjusted FCF between CHF 370-390 million[13, 61] Commercial Developments - Sunrise completed the 3G switch-off, becoming the first operator in Europe with a modern 4G/5G Standalone only network[13] - Sunrise launched new product offerings, including a refresh of the Yallo Portfolio and completion of the UPC customer base migration[13] - Fixed Mobile Convergence continued to increase, up by 1.4% year-over-year[35] - Sunrise extended Swiss National League hockey rights until 2035[25] Customer Metrics - Mobile ARPU trend is improving as subscription revenue stabilizes due to price increases[35] - Fixed ARPU is declining year-over-year but showing an upward trend due to price increases[35] - Net additions growth in Q2 2025 was softer due to reduced commercial activity and price increases[35] Debt and ADS - Sunrise priced new EUR 550 million Senior Secured Notes due 2032 to refinance existing Term Loans[13] - Sunrise Class A American Depositary Shares were delisted from Nasdaq on August 15, 2025, with termination of the sponsored ADS programs planned for around mid-November 2025[13]

Financial Performance - Group net fees decreased by 11% to £972.4 million[10], while operating profit decreased by 56% to £45.6 million[10] - Basic Earnings Per Share (EPS) decreased by 67%[49] - The company delivered approximately £35 million per annum of structural cost savings in FY25[10, 66, 69, 113] Regional Performance - Germany's net fees decreased by 10% to £308.9 million[12], representing 32% of the Group's net fees[12] - UK & Ireland's net fees decreased by 15% to £192.2 million[21], accounting for 20% of the Group's net fees[21], with an operating loss of £(5.8) million[21] - Australia & New Zealand's net fees decreased by 13% to £116.2 million[29], contributing 12% to the Group's net fees[29] - Rest of World's net fees decreased by 8% to £355.1 million[35], making up 36% of the Group's net fees[35] Segment Performance - Temp & Contracting net fees decreased by 7%[10], while Perm net fees decreased by 17%[10] - Temp & Contracting accounted for 62% of Group net fees in FY25[111] Operational Efficiency - Consultant headcount was reduced by 14% year-over-year[10, 65], leading to a 5% increase in consultant net fee productivity[10, 67] - The company closed 29 offices as part of operational restructurings[65]

Financial Performance - The company's operating result increased by 19% to EUR 845 million, driven by business growth and improved experience variance[4] - Operating capital generation (OCG) reached EUR 576 million, putting the company on track to meet its EUR 1.2 billion guidance for 2025[4] - Free cash flow amounted to EUR 442 million, contributing to a cash capital at Holding of EUR 2.0 billion[4] - The group solvency ratio stands at 183%[24] Capital Allocation - The ongoing share buyback program was increased from EUR 200 million to EUR 400 million[4] - An interim dividend of EUR 0.19 per common share was announced, an increase of EUR 0.03 over the 2024 interim dividend[4] Strategic Initiatives - A review is being initiated on a potential relocation of the company's legal domicile and head office to the United States, where Americas share in Aegon Group's financials is 60%[4, 5] Business Segment Performance - In the Americas, new individual life sales increased by 13% due to growth in IUL sales in WFG and a successful product launch in the brokerage channel[11] - Net deposits in mid-sized Retirement Plans in the Americas were supported by a larger takeover deposit from a pooled plan[11] - UK Workplace platform saw net deposits of EUR 2.1 billion, while the Adviser platform experienced net deposits of EUR (1.4) billion[14] - Third-party net deposits in Asset Management's Global Platforms decreased from EUR 5.1 billion to EUR 2.0 billion, driven by alternative fixed income products in 1H25[18] Americas Financial Assets Strategy - Financial Assets actual-to-expected claim ratio is 97%[56] - Financial Assets net face value is 100% or USD 45.1 billion[56]

Financial Performance - Operating revenue reached $2.02 billion, an increase of 8% [15] - Underlying Net Profit After Tax was $377.2 million, up by 43% [15] - The total dividend was 42.50 cents per share, a 19% increase [16] - The total dividend for the year represents a payout of 66% of FY25 net profit [22] FY26 Outlook - The company projects operating revenue in the range of approximately $2.15 billion to $2.25 billion [52] - Net profit after tax is expected to be in the range of approximately $390 million to $440 million [52] - For the first half of FY26, revenue is projected to be approximately $1.075 billion [55] - Net profit after tax for the first half of FY26 is expected to be approximately $200 million [55] Resolutions & Voting - Proxy voting results show strong support for the re-election of directors, with Neville Mitchell receiving 96.9% of the votes [103] - The re-election of Lewis Gradon received 99.5% of the votes [103]

Financial Performance - FY25 Net Operating Profit was $58.5 million, up 60% on FY24[8] - Operating Earnings per Share were 12.48 cents, up 61% on FY24[8] - FY25 Dividends Per Share (DPS) were 7.75 cents, up 82% on FY24[8] - Book NTA per share increased by 5% from $1.31 in FY24 to $1.37 in FY25[8, 57] - Group revenue increased by 39% from $314.4 million in FY24 to $437.3 million in FY25[53] Operational Highlights - 2,768 lots were sold in FY25[10] - 2,642 lots were settled in FY25[12] - Contracts on hand value reached $612 million[13] - The company's gearing was 27.5% at 30 June 2025[8] Strategic Initiatives - A strategic review has commenced to ensure the business is optimally positioned to capitalize on favorable market dynamics[25] - The company aims to unlock short-term and long-term value through the strategic review[27] Land Bank and Future Projects - The company has a pipeline of 30,785 lots with an end value of $13.2 billion[33] - The company plans to launch new projects in FY26 and FY27, including communities and townhouse/apartment sites, with a total GDV of $3.928 billion across 5,944 lots/units[89]

FinVolution Group I n v e s t o r P r e s e n t a t i o n August 2025 This presentation has been prepared by FinVolution Group (the "Company") pursuant to Section 5(d) of the U.S. Securities Act of 1933, as amended (the "Securities Act") solely for informational purposes and is not an offer to buy or sell or a solicitation of an offer to buy or sell any security or instrument or to participate in any investment activity or trading strategy, nor may it or any part of it form the basis of or be relied on in c ...

Results for year ended 30 June 2025 Mick O'Brien, Managing Director Johanna Platt, Chief Financial Officer EQT HOLDINGS LIMITED (ASX: EQT) 21 AUGUST 2025 Investor Presentation For personal use only For personal use only Agenda 1 Business Performance Update Mick O'Brien – Managing Director 2 Financial Review Johanna Platt – Chief Financial Officer 3 Strategy & Outlook Mick O'Brien – Managing Director 4 Questions Strong financial performance – record FUMAS and strong topline growth 02 Expenses turnaround – 2H ...

Financial Performance - The company's statutory NPAT increased by 82% to $149.1 million compared to FY24[9] - Underlying EBITA increased by 25% to $474.2 million compared to FY24[9] - The company achieved an EBITA margin of 4.4%, exceeding the management target of 4.2%[9] - The company's cash conversion was 98%, exceeding the target of >90%[9] - The company's leverage ratio improved to 0.9x net debt to EBITDA, compared to 1.3x at Dec-24[9] - The company achieved annualised gross cost out of $213 million, exceeding the upsized target of $200 million[9] Revenue and Work-in-Hand - The company's FY25 revenue was $10.6 billion[101] - The company's work-in-hand is $35.1 billion[53] Shareholder Returns - The company announced an on-market share buy-back of up to $230 million, representing approximately 5% of issued capital[8, 73, 78] - The company's total dividend increased by 46% on FY24[9, 75] - The company's final dividend is 14.1cps, 100% franked[9] Outlook - The company is targeting underlying earnings and EBITA margin improvement in FY26, with underlying revenue forecast to be flat to slightly lower than FY25 pro forma revenue[84]

Financial Performance - Revenue reached $2482.6 million in FY25, comparable to $2475.1 million in FY24[43] - Underlying Profit Before Tax (PBT) was $22.3 million, compared to $56.8 million in FY24[5] - EBITDA was $110.1 million in FY25, down from $135.0 million in FY24[5] - Net tangible assets (NTA) stood at $1.42 per share[5] Operational Highlights - New car and demo inventory reduced to $343.1 million at FY25, excluding acquisitions since FY24[7,8] - Reduction in new car and demo inventory resulted in $32 million (-8%) decrease[7] - The company has 14+ Chinese brand dealerships[7] - Headcount reduced from 2300 to 1900, leading to lower costs[7] Sales Performance - New vehicle units sold were 31,242 in FY25, compared to 32,429 in FY24[20] - Used vehicle units sold increased to 9,702 in FY25, up from 8,520 in FY24[20] - Service & Parts Revenue increased to $422 million in FY25, compared to $405 million in FY24[20]

Financial Performance - Group revenue increased by 63% year-over-year to $390.4 million [26] - Precision Medicine revenue increased by approximately 30% year-over-year [26] - R&D investment increased by 47% year-over-year [26] - The company maintained positive operating cash flow of $17.7 million [26] - The company invested $241.8 million in strategic M&A [26] Business Segments - RLS revenue was $79.0 million, including third-party sales of PET and SPECT products [28, 29] - Precision Medicine gross margins remained stable at 64% [26, 36] - TMS (excluding RLS) experienced operating expenses that support expansion of global facilities and start-up and integration activities [38] Guidance and Future Outlook - The company reaffirmed FY 2025 revenue guidance of $770 million - $800 million [26, 48] - Research & Development (R&D) expenditure is expected to increase 20% - 25% compared to FY 2024 [49] Strategic Initiatives - The company completed target enrollment of 30 patients for ProstACT Global Phase 3 Part 1 [21, 109, 126] - The company received approval to commence IPAX-BrIGHT pivotal trial in glioblastoma (ex-U S) [21, 126] - The company is planning NDA resubmission for Pixclara® in approximately three months [21, 99]